BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24661671)

  • 21. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
    Waldman SA; Hyslop T; Schulz S; Barkun A; Nielsen K; Haaf J; Bonaccorso C; Li Y; Weinberg DS
    JAMA; 2009 Feb; 301(7):745-52. PubMed ID: 19224751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.
    Lin JE; Li P; Snook AE; Schulz S; Dasgupta A; Hyslop TM; Gibbons AV; Marszlowicz G; Pitari GM; Waldman SA
    Gastroenterology; 2010 Jan; 138(1):241-54. PubMed ID: 19737566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C.
    Abraham TS; Flickinger JC; Waldman SA; Snook AE
    J Immunol; 2019 Feb; 202(4):1301-1310. PubMed ID: 30642983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8
    Walker JM; Rolig AS; Charych DH; Hoch U; Kasiewicz MJ; Rose DC; McNamara MJ; Hilgart-Martiszus IF; Redmond WL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease.
    Snook AE; Li P; Stafford BJ; Faul EJ; Huang L; Birbe RC; Bombonati A; Schulz S; Schnell MJ; Eisenlohr LC; Waldman SA
    Cancer Res; 2009 Apr; 69(8):3537-44. PubMed ID: 19351847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.
    Magee MS; Kraft CL; Abraham TS; Baybutt TR; Marszalowicz GP; Li P; Waldman SA; Snook AE
    Oncoimmunology; 2016; 5(10):e1227897. PubMed ID: 27853651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients.
    Mejia A; Schulz S; Hyslop T; Weinberg DS; Waldman SA
    Expert Rev Mol Diagn; 2009 Nov; 9(8):777-85. PubMed ID: 19895223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GUCY2C molecular staging personalizes colorectal cancer patient management.
    Gong JP; Schulz S; Hyslop T; Waldman SA
    Biomark Med; 2012 Jun; 6(3):339-48. PubMed ID: 22731908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.
    Chang MC; Chen YL; Lin HW; Chiang YC; Chang CF; Hsieh SF; Chen CA; Sun WZ; Cheng WF
    Mol Ther; 2018 Feb; 26(2):404-419. PubMed ID: 29248428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.
    Pattison AM; Blomain ES; Merlino DJ; Wang F; Crissey MA; Kraft CL; Rappaport JA; Snook AE; Lynch JP; Waldman SA
    Infect Immun; 2016 Oct; 84(10):3083-91. PubMed ID: 27481254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice.
    Valentino MA; Lin JE; Snook AE; Li P; Kim GW; Marszalowicz G; Magee MS; Hyslop T; Schulz S; Waldman SA
    J Clin Invest; 2011 Sep; 121(9):3578-88. PubMed ID: 21865642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
    Rappaport JA; Waldman SA
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
    [No Abstract]   [Full Text] [Related]  

  • 36. Optimized Gemcitabine Therapy in Combination with E7 Peptide Immunization Elicits Tumor Cure by Preventing Ag-Specific CTL Inhibition in Animals with Large Established Tumors.
    Jang HY; Han BS; Kwon B; Sin JI
    DNA Cell Biol; 2018 Oct; 37(10):850-860. PubMed ID: 30227079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
    Ni K; Luo T; Nash GT; Lin W
    Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C.
    Romi H; Cohen I; Landau D; Alkrinawi S; Yerushalmi B; Hershkovitz R; Newman-Heiman N; Cutting GR; Ofir R; Sivan S; Birk OS
    Am J Hum Genet; 2012 May; 90(5):893-9. PubMed ID: 22521417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.
    Hannan R; Zhang H; Wallecha A; Singh R; Liu L; Cohen P; Alfieri A; Rothman J; Guha C
    Cancer Immunol Immunother; 2012 Dec; 61(12):2227-38. PubMed ID: 22644735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Molecular-level Changes of Programmed Cell Death Ligand-1 after Radiation Therapy in a BALB/c CT26 Colorectal Mouse Tumor Model.
    Khani Chamani F; Shabani M; Moradi A; Alinejad M; Jalali SA
    Iran J Allergy Asthma Immunol; 2023 Apr; 22(2):163-171. PubMed ID: 37496409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.